查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
mRNA 技術拓展製藥領域
市場調查報告書
商品編碼
1805548

mRNA 技術拓展製藥領域

mRNA Technologies Expanding Pharma Horizons
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告全面分析了 mRNA 技術在藥物研發中的發展，並專注於其在 COVID-19 疫苗以外的應用。報告探討了基於 mRNA 的疫苗和療法的科學和商業進展，包括遞送平台和生產過程的進步，以及環狀 RNA 和自擴增 RNA 等新型療法的出現。報告還重點介紹了人工智慧、奈米技術和基因編輯如何推動 mRNA 設計和應用的創新，並評估了塑造該領域的監管和市場力量。本報告將深入探討各種 mRNA 格式的優點和限制、標靶遞送和免疫原性的課題，以及 mRNA 技術在個人化癌症疫苗、罕見疾病和下一代基因編輯療法等領域的未來潛力。

主要的問題

  • 1.mRNA 技術如何影響疫苗和療法的研發？
  • 2.與線性 mRNA 相比，各種 mRNA 模式的優缺點是什麼？
  • 3.要充分發揮 mRNA 技術的潛力，必須面對哪些課題？
  • 4.環狀 RNA、自擴增 RNA、鹼基編輯和 CRISPR 等新興技術將如何影響 mRNA 模式？
  • 5.基於 mRNA 的疫苗和治療方法的開發將如何影響 mRNA 模式？最新進展
  • 6.mRNA 技術未來應用於更廣泛疾病的潛力
  • 7.製造和交付方面的進步如何提高 mRNA 產品的品質和可近性？
  • 8.開發和商業化基於 mRNA 的產品需要哪些監管考量？
  • 9.人工智慧和機器學習等顛覆性技術如何加速 mRNA 創新？
  • 10.mRNA 治療領域的主要市場驅動力和投資趨勢

主要企業

  • AbbVie
  • Abogen
  • Acuitas
  • Advarra
  • Anima Biotech
  • Arcturus Therapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • BioNTech
  • Bristol Myers Squibb
  • Capstan Therapeutics
  • Certest Biotec
  • Chimeron Bio
  • Circio Holding ASA
  • CirCode
  • Circular Genomics
  • CureVac
  • Cytiva
  • Dropshot Therapeutics
  • Eli Lilly
  • EsoBiotec
  • eTheRNA
  • Ethris
  • Genentech
  • Ginkgo Bioworks
  • In-Cell-Art
  • Longuide Limited Lab
  • Intellia Therapeutics
  • Intra-Cellular Therapies
  • Johnson & Johnson
  • Lonza
  • Merck & Co.
  • Merck KGaA
  • Moderna
  • Novartis
  • Nutcracker Therapeutics
  • Orbital Therapeutics
  • Orna Therapeutics
  • Pfizer
  • Portal Biotechnologies
  • Regulus Therapeutics
  • Rhegen
  • RiboX Therapeutics
  • RNACure
  • Roche
  • Sail Biomedicines
  • Sangamo
  • Sanofi
  • Sartorius Stedim Biotech
  • Sensible Biotechnologies
  • Sirnaomics
  • SpringWorks Therapeutics
  • StemiRNA
  • Strand Therapeutics
  • Translate Bio
  • Tiba Biotech
  • Thermo Fisher Scientific
  • Verve Therapeutics
  • VaxEquity
  • Walvax
  • 4basebio

參加專家的一部分清單

  • Advarra(美國)生物安全性服務擔當執行董事
  • Circio Holding ASA (挪威)CEO
  • Sensible Biotechnologies(英國)CSO兼一起同成立者
  • Sensible Biotechnologies(英國)CEO兼一起同成立者

調查手法:

檔案報告是基於獨立、簡潔的分析，這些分析源自於專有的產業研究以及對產業意見領袖的深入訪談。該報告對製藥企業高管需要了解的關鍵發展和市場趨勢進行了詳細分析，以應對未來的機會和課題。每份報告的重點都基於對二手文獻的回顧和已發現的知識差距。基於這些初步研究，我們制定了基於證據、專家指導的討論指南，以確保我們的研究能夠解答最重要的問題。此外，我們採用嚴格的篩選標準，以確保受訪者擁有就該主題發言所需的經驗、知識和地位。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥領域，為生物製藥專業人士和決策者提供深入可行的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助客戶了解新興趨勢並有效應對複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖 (KOL) 的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家訪談和數據，以及持續的市場監測，確保您能夠全面了解市場動態。我們的報告涵蓋 40 多個活躍的疾病領域，並提供醫生情報，包括關鍵意見領袖洞察和定量醫生調查，以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入等領域問題的看法，使您能夠做出更明智的數據驅動決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report provides a comprehensive analysis of the evolving landscape of mRNA technologies in pharmaceutical development, with a focus on their impact beyond COVID-19 vaccines. It examines the scientific and commercial progress of mRNA-based vaccines and therapeutics, including advances in delivery platforms, manufacturing and the emergence of novel modalities, such as circular RNA and self-amplifying RNA. The report also highlights how AI, nanotechnology and gene editing are driving innovation in mRNA design and application, while assessing the regulatory and market forces shaping the sector. Gain insights into the advantages and limitations of different mRNA formats, the challenges of targeted delivery and immunogenicity and the future potential of mRNA technologies in areas such as personalised cancer vaccines, rare diseases and next-generation gene editing therapies.

Key Questions Answered:

  • 1. How has mRNA technology impacted the development of vaccines and therapeutics?
  • 2. What are the advantages and disadvantages of different mRNA modalities compared to linear mRNA?
  • 3. What challenges must be addressed to fully realise the potential of mRNA technologies?
  • 4. How might novel technologies like circular RNA, self-amplifying RNA, base editing and CRISPR influence the mRNA landscape?
  • 5. What are the latest trends in mRNA-based vaccine and therapeutic development?
  • 6. What future opportunities exist for applying mRNA technology to a broader range of diseases?
  • 7. How are advances in manufacturing and delivery improving mRNA product quality and accessibility?
  • 8. What regulatory considerations are shaping the development and commercialisation of mRNA-based products?
  • 9. How are disruptive technologies, such as AI and machine learning, accelerating mRNA innovation?
  • 10. What are the key market drivers and investment trends in the mRNA therapeutics sector?

Key Companies:

  • AbbVie
  • Abogen
  • Acuitas
  • Advarra
  • Anima Biotech
  • Arcturus Therapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • BioNTech
  • Bristol Myers Squibb
  • Capstan Therapeutics
  • Certest Biotec
  • Chimeron Bio
  • Circio Holding ASA
  • CirCode
  • Circular Genomics
  • CureVac
  • Cytiva
  • Dropshot Therapeutics
  • Eli Lilly
  • EsoBiotec
  • eTheRNA
  • Ethris
  • Genentech
  • Ginkgo Bioworks
  • In-Cell-Art
  • Longuide Limited Lab
  • Intellia Therapeutics
  • Intra-Cellular Therapies
  • Johnson & Johnson
  • Lonza
  • Merck & Co.
  • Merck KGaA
  • Moderna
  • Novartis
  • Nutcracker Therapeutics
  • Orbital Therapeutics
  • Orna Therapeutics
  • Pfizer
  • Portal Biotechnologies
  • Regulus Therapeutics
  • Rhegen
  • RiboX Therapeutics
  • RNACure
  • Roche
  • Sail Biomedicines
  • Sangamo
  • Sanofi
  • Sartorius Stedim Biotech
  • Sensible Biotechnologies
  • Sirnaomics
  • SpringWorks Therapeutics
  • StemiRNA
  • Strand Therapeutics
  • Translate Bio
  • Tiba Biotech
  • Thermo Fisher Scientific
  • Verve Therapeutics
  • VaxEquity
  • Walvax
  • 4basebio

Partial List of Participating Experts:

  • Executive Director of Biosafety Services, Advarra, US
  • CEO, Circio Holding ASA, Norway
  • CSO and co-founder, Sensible Biotechnologies, UK
  • CEO and co-founder, Sensible Biotechnologies, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.